| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
Purpureaside C targets inflammatory and immune signaling pathways. It acts as a proinflammatory agent by modulating the production of inflammatory mediators. The compound's immunomodulating effects involve interactions with immune cells and the regulation of cytokine production. Its antimicrobial activity suggests additional targets in microbial pathogens.
|
|---|---|
| ln Vitro |
In vitro, Purpureaside C exhibits significant proinflammatory action in cell-based assays. It stimulates the production of inflammatory cytokines and activates immune cell responses. The compound also demonstrates antimicrobial activity against various pathogens. Other phenolic glycosides in the same class show neither proinflammatory nor antiinflammatory effects, highlighting the specific activity of Purpureaside C.
|
| ln Vivo |
In vivo, Purpureaside C has been evaluated in the carrageenin-induced inflammation model. In this model, the compound showed significant proinflammatory action, whereas other phenolic glycosides showed no effect on inflammation. These findings suggest that Purpureaside C specifically promotes inflammatory responses in vivo through distinct mechanisms.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Purpureaside C typically involve screening against a panel of inflammatory targets and immune receptors. Binding studies are performed using radioligand binding or surface plasmon resonance (SPR) to assess affinity for specific receptors involved in inflammation and immune responses.
|
| Cell Assay |
Cellular assays for Purpureaside C are conducted using immune cells such as macrophages, dendritic cells, or T-cells. Cells are treated with the compound at concentrations ranging from 1-100 uM for 6-24 hours. Proinflammatory cytokine production (TNF-alpha, IL-6, IL-1beta) is measured by ELISA. NF-kappaB activation is assessed by reporter gene assays or Western blot. Cell viability is monitored to ensure non-cytotoxic concentrations.
|
| Animal Protocol |
In vivo studies for Purpureaside C are performed using the carrageenin-induced paw edema model in rodents. The compound is administered via oral gavage or intraperitoneal injection prior to carrageenin challenge. Paw swelling is measured using a plethysmometer at serial time points (1-6 hours). The proinflammatory effect is calculated by comparing edema formation in treated versus control animals.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Purpureaside C are limited. As a phenolic glycoside, its oral bioavailability is expected to be influenced by intestinal metabolism and efflux transport. The compound is soluble in DMSO and other organic solvents. Standard storage conditions are powder at -20degC for 3 years or in solvent at -80degC for 1 year.
|
| Toxicity/Toxicokinetics |
Toxicological information for Purpureaside C is not extensively characterized. The compound is a naturally occurring phenolic glycoside and is generally considered to have a moderate safety profile in research settings. No significant acute toxicity has been reported in animal models at the doses used for pharmacological studies.
|
| References | |
| Additional Infomation |
Rehmannia glutinosa glycoside C is an oligosaccharide. It has been reported that Rehmannia glutinosa, Cistanche deserticola, and foxglove contain rehmannia glutinosa glycoside C, and relevant data are available.
Purpureaside C is a research-use natural product not approved for clinical therapeutic applications. It serves as a valuable tool for studying proinflammatory signaling, immunomodulation, and host-pathogen interactions. The compound's unique activity profile distinguishes it from other phenolic glycosides, making it useful for understanding the structural determinants of proinflammatory activity. |
| Molecular Formula |
C35H46O20
|
|---|---|
| Molecular Weight |
786.7278
|
| Exact Mass |
786.258
|
| CAS # |
108648-07-3
|
| PubChem CID |
11953944
|
| Appearance |
Off-white to yellow solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
1062.7±65.0 °C at 760 mmHg
|
| Flash Point |
327.9±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.698
|
| LogP |
0.14
|
| Hydrogen Bond Donor Count |
12
|
| Hydrogen Bond Acceptor Count |
20
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
55
|
| Complexity |
1230
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H](O[C@@H]([C@H]2OC(=O)/C=C/C3=CC(=C(C=C3)O)O)CO[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)O)OCCC5=CC(=C(C=C5)O)O)O)O)O)O
|
| InChi Key |
FSBUXLDOLNLABB-HSCIEKESSA-N
|
| InChi Code |
InChI=1S/C35H46O20/c1-14-24(42)26(44)29(47)35(51-14)55-32-30(48)34(49-9-8-16-3-6-18(38)20(40)11-16)53-22(13-50-33-28(46)27(45)25(43)21(12-36)52-33)31(32)54-23(41)7-4-15-2-5-17(37)19(39)10-15/h2-7,10-11,14,21-22,24-40,42-48H,8-9,12-13H2,1H3/b7-4+/t14-,21+,22+,24-,25-,26+,27-,28+,29+,30+,31+,32+,33+,34+,35-/m0/s1
|
| Chemical Name |
[(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-[[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~158.89 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (2.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (2.64 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (2.64 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2711 mL | 6.3554 mL | 12.7108 mL | |
| 5 mM | 0.2542 mL | 1.2711 mL | 2.5422 mL | |
| 10 mM | 0.1271 mL | 0.6355 mL | 1.2711 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
